Last updated: February 24, 2026
What is NDC 66993-0700?
NDC 66993-0700 refers to a specific drug product, identified through the National Drug Code (NDC) system. The NDC 66993-0700 corresponds to Ropinirole Hydrochloride Tablets, 0.25 mg. This medication is primarily used to manage Parkinson’s disease and restless legs syndrome.
Market Overview
Current Market Size
- The global Parkinson’s disease treatment market was valued at approximately USD 4.6 billion in 2022.
- Ropinirole, as a first-line device for Parkinson’s disease and RLS, accounts for roughly 15-20% of the market share.
- The U.S. prescription volume for Ropinirole (all strengths) in 2022 was approximately 1.2 million prescriptions across multiple formulations.
Competitive Landscape
- Major competitors include generic formulations of Ropinirole, along with branded options such as Requip (by GlaxoSmithKline).
- Market share for generics exceeds 60%, reflecting a shift toward lower-cost options.
- New entrants are limited due to patent expirations, with most competition centered around price competition among generics.
Regulatory Status
- The drug has full FDA approval for Parkinson’s disease and RLS.
- The patent for the original branded product expired in 2012; generic versions have dominated since.
Key Market Drivers
- Rising prevalence of Parkinson’s disease, projected to reach 12 million globally by 2040.
- Growing RLS awareness and diagnosis.
- Cost reduction initiatives favoring generic medication adoption.
Price Projection Analysis
Current Pricing Landscape
| Formulation |
Average Wholesale Price (AWP) |
Estimated Retail Price |
Market Share (Generics) |
| Ropinirole 0.25 mg tablets |
USD 0.15 per tablet |
USD 0.25 per tablet |
65% (2023) |
The AWP for 0.25 mg tablets has seen a stable range of USD 0.14–0.16 over the past year. The retail price typically doubles the wholesale price, with slight variations based on pharmacy contracts and insurance coverage.
Price Trends and Projections (Next 2-5 Years)
- Short-term (1-2 years): Prices likely remain stable due to the mature generic market and minimal patent activity.
- Medium-term (3-5 years): Slight downward pressure is expected from increased production efficiencies and potential biosimilar or alternative RLS treatments entering the market.
- Impact of Policy Changes: Price negotiations under Medicare, Medicaid, and commercial payers may introduce discounts, influencing retail prices downward by approximately 3-7%.
Pricing Implications of Market Dynamics
- As demand increases with the aging population, volume sales are expected to compensate for slight price declines.
- Manufacturers may streamline manufacturing to reduce costs, enabling further price reductions.
- Introduction of alternative therapies or combination drugs could pressure Ropinirole prices.
Investment and R&D Outlook
- No current pipeline developments directly impact Ropinirole’s price in the next 2-3 years.
- R&D focus shifts toward novel Parkinson’s treatments, which may influence the market share of existing drugs.
Patent and Regulatory Considerations
- The primary patent for the original branded product expired in 2012.
- No recent patent applications or exclusivity extensions announced.
- Bioequivalence studies for generics set the stage for continued price competition.
Summary
Ropinirole (NDC 66993-0700) operates in an established, highly competitive market mostly dominated by generics. Prices are stable, with minor downward trends expected over the medium term due to market saturation, manufacturing efficiencies, and healthcare policy influences.
Key Takeaways
- The drug’s market size remains significant, driven by Parkinson’s and RLS prevalence.
- The generic landscape renders pricing relatively stable but competitive.
- Price projections suggest modest declines, influenced by policy and technological advances.
- No immediate pipeline threats or patent protections will alter the current market dynamics in the short term.
- Investment strategies should consider volume growth amidst steady or declining unit prices.
FAQs
Q1: How does the price of NDC 66993-0700 compare to other formulations of Ropinirole?
The 0.25 mg tablets typically price lower than higher-dose formulations due to dosage and manufacturing costs. Prices for higher doses range from USD 0.20 to USD 0.30 per tablet.
Q2: Are there biosimilar versions of Ropinirole currently approved?
No, biosimilar equivalents are not applicable as Ropinirole is chemically synthesized, not biologic. However, multiple generic versions exist.
Q3: What factors could significantly change the price of this drug?
Introduction of new therapies, regulatory price controls, or large-scale procurement discounts could impact prices more than market competition.
Q4: What is the typical profit margin for generic manufacturers of this drug?
Margins are generally between 10-15%, influenced by manufacturing costs, pricing strategies, and reimbursement rates.
Q5: How long will current patent protections influence the market?
Since most patents expired in 2012, current prices are driven by generic competition, with no patent-related innovations expected to impact pricing short-term.
References
[1] MarketWatch. (2023). Parkinson’s Disease Treatment Market Size, Share & Trends. Available at: https://www.marketwatch.com
[2] IQVIA. (2022). Prescription Drug Trends Data.
[3] FDA. (2022). New Drug Approvals and Patent Life. Available at: https://www.fda.gov
[4] GlobalData. (2023). Ropinirole Market Share and Price Trends.
